Related Experiment Video
Updated: Aug 15, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
The clinical management of hyperphosphatemia
1Klinikum der Universitat Heidelberg, Heidelberg, Germany. E.Ritz@t-online.de
Hyperphosphatemia, common in end-stage renal disease (ESRD), leads to serious complications like bone disease and vascular calcification. Emerging therapies offer new hope for managing phosphorus levels and improving patient outcomes.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Endocrinology
Background:
- End-stage renal disease (ESRD) patients often develop hyperphosphatemia due to impaired kidney function.
- Dialysis is insufficient to fully correct phosphorus levels, leading to significant health risks.
Purpose of the Study:
- To review the consequences of hyperphosphatemia in ESRD patients.
- To discuss recent advancements in treating hyperphosphatemia and its associated complications.
Main Methods:
- Literature review of studies on hyperphosphatemia in ESRD.
- Analysis of current and emerging therapeutic strategies.
Main Results:
- Hyperphosphatemia contributes to secondary hyperparathyroidism, osteodystrophy, and vascular calcification.
- Vascular calcification is linked to increased cardiovascular disease, mortality, and morbidity.
Conclusions:
- Reducing phosphorus levels is a critical therapeutic goal in ESRD.
- Emerging therapies show promise in mitigating hyperphosphatemia-related complications, including bone disease and calcification.
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Peritoneal Dialysis III: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease III: Interprofessional Care

